Brain Advance Access originally published online on January 19, 2005
Brain 2005 128(3):559-569; doi:10.1093/brain/awh374
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors
1 Wallenberg Neuroscience Center, Division of Neurobiology, Lund University, Lund, Sweden, 2 Department of Neurology, Hannover Medical School, Hannover, Germany, 3 Department of Molecular Genetics and Microbiology, 4 Powell Gene Therapy Center, McKnight Brain Institute, University of Florida College of Medicine, and 5 Department of Neuroscience, McKnight Brain Institute, Gainesville, FL, USA
Correspondence to: Thomas Carlsson, Wallenberg Neuroscience Center, BMC A11, 221 84, Lund, Sweden E-mail: Thomas.Carlsson{at}mphy.lu.se
Dyskinesias are a major complication of long-term L-3,4-dihydroxyphenylalanine (L-DOPA) treatment in Parkinson's disease, and are believed to result from the intermittent and pulsatile supply of L-DOPA. Daily injections of L-DOPA can prime similar abnormal involuntary movements of the limb, orolingual and axial muscles in rats rendered parkinsonian by destruction of the nigrostriatal dopamine (DA) neurons. In this study we used 33 rats with severe nigrostriatal dopamine depletion and showed that in vivo gene transfer of the DA-synthetic enzymes tyrosine hydroxylase (TH) and GTP cyclohydrolase 1 (GCH1) using recombinant adeno-associated virus vectors can provide a constant source of DOPA production locally in the striatum, at a level that is effective in reducing L-DOPA-induced dyskinesias by >85%, and reverse lesion-induced motor impairments. Furthermore, the abnormal expression of 
FosB, prodynorphin and preproenkephalin mRNA within the striatal projection neurons normally seen in dyskinetic animals was completely reversed by TH–GCH1 gene transfer. These findings form a strong basis for replacing, or supplementing, conventional systemic L-DOPA therapy by continuous intrastriatal DOPA using in vivo gene transfer in the treatment of patients with advanced Parkinson's disease.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Bjorklund, T. Bjorklund, and D. Kirik Gene Therapy for Dopamine Replacement in Parkinsons Disease Science Translational Medicine, October 14, 2009; 1(2): 2ps2 - 2ps2. [Full Text] [PDF]
|
|
|
|
|
|
B. Jarraya, S. Boulet, G. Scott Ralph, C. Jan, G. Bonvento, M. Azzouz, J. E. Miskin, M. Shin, T. Delzescaux, X. Drouot, et al. Dopamine Gene Therapy for Parkinson's Disease in a Nonhuman Primate Without Associated Dyskinesia Science Translational Medicine, October 14, 2009; 1(2): 2ra4 - 2ra4. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Devos, C. Moreau, A. Destee, J. M. Gerard, J.-A. Elosegi, and P. A. LeWitt Levodopa for Parkinson's Disease N. Engl. J. Med., February 26, 2009; 360(9): 935 - 936. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Leriche, T. Bjorklund, N. Breysse, L. Besret, M.-C. Gregoire, T. Carlsson, F. Dolle, R. J. Mandel, N. Deglon, P. Hantraye, et al. Positron Emission Tomography Imaging Demonstrates Correlation between Behavioral Recovery and Correction of Dopamine Neurotransmission after Gene Therapy J. Neurosci., February 4, 2009; 29(5): 1544 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Munoz, Q. Li, F. Gardoni, E. Marcello, C. Qin, T. Carlsson, D. Kirik, M. Di Luca, A. Bjorklund, E. Bezard, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia Brain, December 1, 2008; 131(12): 3380 - 3394. [Abstract] [Full Text] [PDF]
|
|